LD-2 disclosure · 3rd Quarter - Report
VERTEX PHARMACEUTICALS INCORPORATED
Client
- Location
- Massachusetts · United States of America
Registrant
- Description
- Global biotechnology company
- Location
- Boston, Massachusetts, United States of America
Lobbying activities
4 issuesHealth Issues
Issues related to health care and prescription drug pricing in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169); H.R. 5801 - HELP Copays Act; H.R. 7506 - New Era of Preventing End-Stage Kidney Disease Act; H.Res. 1330 - Expressing support for the designation of September 2022 as "Sickle Cell Disease Awareness Month".
LobbyistsSAMANTHA VENTIMIGLIA · SCOTT BARNES · MATTHEW O SCHUMAKER · KWAMME ANDERSON
TargetedSENATE · HOUSE OF REPRESENTATIVES
Taxation/Internal Revenue Code
Issues related to corporate and international tax policy and research and development tax credits; Issues related to the Orphan Drug Tax Credit; Issues related to corporate and international tax policy in H.R. 5376 - Build Back Better Act, Inflation Reduction Act of 2022 (PL 117-169).
LobbyistsSAMANTHA VENTIMIGLIA · SCOTT BARNES · MATTHEW O SCHUMAKER · KWAMME ANDERSON
TargetedSENATE · HOUSE OF REPRESENTATIVES
Budget/Appropriations
Issues related to funding for the Food and Drug Administration S. 4661/H.R. 8239 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2023; Issues related to the implementation of the recommendations within The National Academies of Sciences, Engineering, and Medicine (NASEM) report "Addressing Sickle Cell Disease: A Strategic Plan and Blueprint for Action" S. 4659/H.R. 8295 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023.
